CURRICULUM VITAE

Revised October 2016

NAME:	Anthony Michael Sliwinski, M.D.
BIRTHDATE:	5/18/61
BIRTHPLACE:	Washington, D.C.
CITIZENSHIP:	USA
BUSINESS ADDRESS:	Virginia Urology Center, P.C. 9105 Stony Point Drive, Richmond, VA 23235 14051 St. Francis Blvd., 2nd Flr., Ste. 2001, Midlothian, VA 23114
TELEPHONE:	Office: 330-9105
LICENSURE:	Virginia 0101-043462 DEA BS2660834
CERTIFICATION:	American Board of Urology, 2/93; Recertified 10/2010

EDUCATION:

University of Virginia
Charlottesville, VA
B.A. Chemistry 1979-1982

Georgetown University School of Medicine
Washington, D.C.
M.D. 8/1982-6/1986

Medical College of Virginia
Richmond, VA

Internship in Surgery	7/1986-6/1987
Junior Assistant Resident in Surgery	7/1987-6/1988
Assistant Resident in Urology	7/1988-6/1989
Senior Assistant Resident in Urology	7/1989-6/1990
Chief Resident in Urology	7/1990-6/1991

EMPLOYMENT HISTORY:

McGuire Clinic, July 1991-1994
Urologist--Virginia Urology, August 1994 to present

HOSPITAL APPOINTMENTS:

CJW Medical Center, Richmond, VA (Chippenham & JohnstonWillis)
Henrico Doctors Hospital, Richmond, VA (Forest, Parham & Retreat)
Memorial Regional Medical Center, Mechanicsville, VA
St. Francis Medical Center
St. Mary's Hospital, Richmond, VA
Sheltering Arms Hospital, Richmond, VA
Urosurgical Center of Richmond, Richmond, VA

MEMBERSHIPS:

American Urological Association
Richmond Academy of Medicine
Medical Society of Virginia
Society of Urologic Prosthetic Surgeons (SUPS)

PRESENTATIONS:

5/28/92	Impotence: Geddings D., Osbon Foundation
9/8/92	Prostate Cancer: Hanover County Chapter of American Cancer Society
9/15/92	Urology: BLAB TV, 60 Minutes
2/26/93	Management of BPH: Southside Regional Medical Center, CME
3/17/93	Management of BPH: Good Samaritan Hospital Grand Rounds, CME
2/21-23/94	Management of Benign Prostatic Hyperplasia: A Urologist's Perspective, Medical Update, The Washington Urologic Society
7/98	New Developments in Erectile Dysfunction: Virginia Academy of Family Practice 50th Annual Mtg., Virginia Beach Convention Center
10/98	Incontinence: BLAB TV, 60 min.
1/99	Alpha Blockade International Conference on Impotence, Puerto Rico
7/00	Men's Health Issues: BLAB TV w/John Goodman; 60 min.
2/01	Overactive Bladder, Grand Rounds Presentation: Mary Washington Hospital
3/01	Overactive Bladder, Grand Rounds Presentation: MCV Dept. of OB/GYN
10/03	Overactive Bladder, Grand Rounds Presentation: Ohio State University School of Medicine
3/04	Alternative Medicine in Treatment of Overactive Bladder and Irritable Bowel Syndrome: SUNA National Conference on Pelvic Floor Disorders, Chicago, IL
3/04	NUTS to LUTS: SUNA National Conference on Pelvic Floor Disorders, Chicago, IL
3/04	Alternative Medicine in Treatment of Overactive Bladder and Irritable Bowel Syndrome: Urologic Nurses Association Seminar, MCV, Richmond, VA
4/24/04	Topic: Erectile Dysfunction, Urological Update 2004, Virginia Urology Center, Richmond, VA

RESEARCH: PRINCIPAL INVESTIGATOR EXPERIENCE

Aquinox Pharmaceuticals 2016
ProtocolAQX-1125-301
Leadership 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doxes of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by 14 or 40 Week Extension Periods

Allergan 2016
Protocol 191622-133
An Exploratory Study of the Safety and Efficacy of BOTOX for the Treatment of Premature Ejaculation

Auxilium Pharmaceuticals 2014
Protocol AUX-CC-810
Phase 4:Long-term Safety, Curvature Deformity Characterization and Immunogenicity over Time in Subjects Previously Treated with AA4500 for Peyronie's Disease in Studies AUX-CC-802, AUX-CC-803, AUX CC 804, AND AUX CC 806

Afferent Pharmaceuticals 2013
Protocol AF219-005
A Four-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of AF-219 in Subjects with Interstitial Cystitis /Bladder Pain Syndrome

Vantia Ltd 2012
Protocol 483-009
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose Range Finding Study to Determine the Efficacy and Safety of Fedovapagon in Men with Nocturia

Auxilium Pharmaceuticals 2011
Protocol AUX-CC-802
Title: A Phase 3, Open-Label Study of the Safety and Effectiveness of AA4500 Administered Twice per Treatment Cycle for up To Four Treatment Cycles (2x4) In Men With Peyronie's Disease

Ferring Pharmaceuticals 2007
Protocol FE9992026 CS31
A Multi-Center Extension Study Investigating the Long Term Efficacy and Safety of a Fest-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults

Ferring Pharmaceuticals 2007
Protocol FE992026 CS29
A Randomized, Double-Blind, Placebo Controlled, Parallel, Group, Multi-Center Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults

Lilly Research Laboratories 2004
Protocol: F1J-MC-SBCT
Effect of Duloxetine on Valsalva Leak point Pressure and Quantitative Rhabdosphincter Electromyography Measures in Women with Stress Urinary Incontinence

EDAP TMS 2003
WIRB Protocol #20052702
EDAP Ablatherm Integrated Imaging High Intensity Focused Ultrasound (HIFU) indicated for Treatment of Low Risk, Localized Prostate Cancer.

Bayer Corporation 2002
Protocol: 10867
A Randomized, Double Blind, Parallel Group, Multi-Center Study to Investigate the Time to Onset of Action of 20 mg of Vardenafil Compared to Placebo in Males with Erectile Dysfunction.

Bayer Corporation 2002
Protocol 10806
A Randomized, Double-Blind, Multi-Center, Two-Arm Study to Investigate the Safety and Tolerability of Flexible Doses of Vardenafil or Sildenafil Given On Demand in African American, Hispanic, and Caucasian Males with Erectile Dysfunction.

Bayer Corporation 2001
Protocol 100285
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, fixed-Dose, Parallel group, Three-Month Comparison Study to Investigate the Efficacy and Safety of the Phosphodiesterase Type V Inhibitor BAY 38-9456

Bayer Corporation 2001
Protocol 10125
A Randomised, Double-Blind, Multi-Centre, Fixed Dose, Parallel-Group Twelve Month Study to Investigate the Safety and Tolerability of the Phosphodiesterase Type V Inhibitor BAY-38-9456 in the Treatment of Patients with Erectile Dysfunction in Comparison with Sildenafil.

TAP Holdings Inc 1999
Protocol M99-038
A Phase III, Six-Month, Long-Term, Open-Label, Flexible Dose, Safety Extension Study of Uprima Tablets (2, 3, and 4 mg) in the Treatment of Male Erectile Dysfunction

TAP Holdings Inc 1998
Protocol M98-876
A Phase III At Home Use Study Evaluating the Efficacy and Safety of Escalating Doses of Apomorphine SL to 2, 4 and 5 mg in the Treatment of Male Erectile Dysfunction

TAP Holdings Inc 1998
Protocol M97-682
A Phase Three Long-Term, Open Label, Flexible Dose, Safety Extension Study of Apomorphine SL Tablets in the Treatment of Male Erectile Dysfunction.

TAP Holdings Inc 1997
Protocol M97-763
A Phase III Efficacy and Safety Study Comparing Escalating Doses of Apomorphine SL to 5 mg or 6 mg Doses of Apomorphine SL or Placebo in the Treatment of Male Erectile Dysfunction

1991-94
Ongoing Phase III Clinical Trial: The PLESS Trial: Long term efficacy of Proscar (Finasteride)

1991
MCV clinical experience with lower genitourinary trauma, 1972-present (paper presented at Mid-Atlantic AUA Regional Meeting, September 1990). 2nd prize winner, Virginia Section of American College of Surgeons, Trauma Presentations, October 1990 (paper pending publication)

1989 (Fall)
Testicular infarction in association with intra-aortic balloon pump (accepted for publication in Urology)

1983 (Spring)
A protocol for the determination of Antabuse (Disulfuram) in human plasma or serum

1982 (Spring)
The effect of substrate on the activity of several ATPases